REVIEW ARTICLE E. David Crawford, Thomas W. Flaig;ONCOLOGY Vol. 26 No. 1
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. Future study is needed to define the optimal sequencing and potential combinations of these new agents.
REVIEW ARTICLE Kyle O. Rove, E. David Crawford;ONCOLOGY Vol. 25 No. 14
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
REVIEW ARTICLE Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
CLINICAL QUANDARIES Waseem Khaliq, Ikechukwu Uzoaru, et al; ONCOLOGY Vol. 24 No. 9
Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
SECOND OPINION Elaine T. Lam et al;ONCOLOGY Vol. 25 No. 9
The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass. He underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm.
SECOND OPINION Thomas W. Flaig, Francisco G. La Rosa, et al;ONCOLOGY Vol. 23 No. 2
The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.
Over the last decade, robotic-assisted laparoscopic prostatectomy (RALP) has rapidly gained in popularity, primarily for three reasons: the enthusiasm of surgeons keen to try something new, medical marketing, and patients’ desire to avoid side effects from surgery.
• Hopes and Dreams for Quality Improvement in Radical Prostatectomy
This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin).
• Radium-223: Down to the Bone, and Less Is More • An Alpha Edge?
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction... More »
Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic... More »
The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in... More »
Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has... More »
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
There is no question that the robot has leveled the playing field. It has allowed more surgeons to offer patients a minimally invasive approach. In terms of perioperative outcomes, there is clear evidence showing shorter hospital stays, less blood loss, lower complication rates, and shorter convalescence with robotic-assisted laparoscopic prostatectomy.
Over the last decade, robotic-assisted laparoscopic prostatectomy (RALP) has rapidly gained in popularity, primarily for three reasons: the enthusiasm of surgeons keen to try something new, medical marketing, and patients’ desire to avoid side effects from surgery.
In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non–clear cell RCC.
In this article, we provide the historical background and rationale for hypofractionated prostate cancer treatment, discuss the potential benefits and risks of prostate hypofractionation, and review the clinical evidence regarding the effectiveness of hypofractionated radiation therapy for prostate cancer.
This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin).
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
An asymptomatic, 57-year-old man underwent a prostatic biopsy.
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
